ClearPoint Neuro Q3 revenue $5.8M (+12% YoY); biologics & drug delivery up 55% to $3.5M

ClearPoint Neuro, Inc.

2023-Q3 EPS reported -$0.71 revenue$17,145,000

Revenue $5.8M, +12% YoY; biologics & drug delivery $3.5M (+55%) driven by preclinical services.
Gross margin 57% vs 71% prior year due to lower-margin preclinical services and facility transition.
Operational cash burn $1.8M, lowest since 2020; cash $24.3M at Sept 30.
FY 2023 revenue guidance narrowed to $23-25M, representing 11-18% growth.
Entered new strategic biologics agreements; submitted three stereotactic products and updated software to FDA.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

ClearPoint Neuro, Inc. reported third quarter ended September 30, 2023 results: revenue $5.8 million, net income ($0.34) per diluted share, EPS ($0.34) per diluted share. Guidance reaffirmed.

Period: third quarter ended September 30, 2023
Revenue: $5.8 million
Net income: ($0.34) per diluted share
EPS: ($0.34) per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights • Reported quarterly revenue of $5.8 million, a 12% year-over-year increase; • Increased biologics and drug delivery revenue to $3.5 million, a 55% year-over-year increase; • Operational cash burn of $1.8 million, the

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-23-000114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.